ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 112 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.89 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,633,979 | -31.4% | 1,698,391 | +3.9% | 0.00% | -50.0% |
| Q2 2023 | $16,953,031 | +209.7% | 1,634,815 | +141.6% | 0.00% | +100.0% |
| Q1 2023 | $5,473,840 | +147.5% | 676,618 | +381.9% | 0.00% | – |
| Q4 2022 | $2,211,364 | -16.3% | 140,404 | -16.3% | 0.00% | – |
| Q3 2022 | $2,641,000 | +17.4% | 167,812 | +4.2% | 0.00% | – |
| Q2 2022 | $2,249,000 | +322.7% | 161,110 | +420.7% | 0.00% | – |
| Q1 2022 | $532,000 | -14.6% | 30,939 | -27.8% | 0.00% | – |
| Q4 2021 | $623,000 | +6.5% | 42,869 | +32.0% | 0.00% | – |
| Q3 2021 | $585,000 | +42.7% | 32,472 | +39.1% | 0.00% | – |
| Q2 2021 | $410,000 | +83.0% | 23,339 | +163.0% | 0.00% | – |
| Q1 2021 | $224,000 | +89.8% | 8,874 | -51.2% | 0.00% | – |
| Q4 2020 | $118,000 | +126.9% | 18,203 | -10.1% | 0.00% | – |
| Q3 2020 | $52,000 | +136.4% | 20,259 | +49.6% | 0.00% | – |
| Q2 2020 | $22,000 | +633.3% | 13,546 | +254.4% | 0.00% | – |
| Q1 2020 | $3,000 | -99.9% | 3,822 | -99.8% | 0.00% | -100.0% |
| Q4 2019 | $4,761,000 | +155.1% | 2,518,982 | +45.8% | 0.00% | – |
| Q3 2019 | $1,866,000 | +408.4% | 1,728,141 | +932.6% | 0.00% | – |
| Q2 2019 | $367,000 | -70.4% | 167,362 | -19.1% | 0.00% | – |
| Q1 2019 | $1,238,000 | +0.3% | 206,755 | +23.8% | 0.00% | – |
| Q4 2018 | $1,234,000 | -77.9% | 167,043 | -56.5% | 0.00% | -100.0% |
| Q3 2018 | $5,573,000 | +323.2% | 383,818 | +481.8% | 0.00% | – |
| Q2 2018 | $1,317,000 | -35.5% | 65,971 | -43.4% | 0.00% | -100.0% |
| Q1 2018 | $2,042,000 | -55.9% | 116,578 | -37.9% | 0.00% | 0.0% |
| Q4 2017 | $4,629,000 | +443.9% | 187,715 | +469.2% | 0.00% | – |
| Q3 2017 | $851,000 | +57.3% | 32,978 | +65.1% | 0.00% | – |
| Q2 2017 | $541,000 | -53.6% | 19,974 | -48.9% | 0.00% | – |
| Q1 2017 | $1,166,000 | -63.4% | 39,060 | -66.8% | 0.00% | -100.0% |
| Q4 2016 | $3,190,000 | +362.3% | 117,612 | +336.6% | 0.00% | – |
| Q3 2016 | $690,000 | +34400.0% | 26,937 | +23528.9% | 0.00% | – |
| Q2 2016 | $2,000 | -81.8% | 114 | -70.8% | 0.00% | – |
| Q4 2015 | $11,000 | – | 391 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |